Spatially Controlled Capture and Site‐Resolved Analysis of Single Extracellular Vesicles

Why It Matters

Precise single‑EV analysis eliminates signal ambiguity, enabling more reliable liquid‑biopsy biomarkers and accelerating nanomedicine diagnostics.

Key Takeaways

• >99% EV capture in nanowell arrays with PDMS clearing step
• Mask‑gated image analysis provides site‑specific fluorescence, low background
• Detects HER2‑positive EVs, tracks programmed mixture ratios accurately
• Adaptable to plasma EVs, multi‑channel imaging, and nanoparticle co‑patterning

Pulse Analysis

Extracellular vesicles (EVs) have emerged as a rich source of disease biomarkers, yet conventional bulk assays mask the heterogeneity of individual particles. Current fluorescence‑based platforms often suffer from random particle deposition on continuous surfaces, leading to overlapping signals and high background. The new nanowell‑array approach addresses these limitations by physically isolating each EV in a defined micro‑cavity and using a bright‑field mask to gate fluorescence read‑outs, thereby delivering unambiguous, single‑site measurements that are essential for accurate quantification.

The technical advantages translate directly into diagnostic power. By achieving over 99 % capture efficiency and near‑zero background, the platform can resolve subtle differences in EV composition, such as HER2 expression on breast‑cancer‑derived vesicles—a clinically relevant target for therapy selection. Moreover, the method faithfully reproduces programmed EV mixture ratios, demonstrating quantitative reliability. Its compatibility with plasma samples, multi‑color imaging, and co‑patterned nanoparticles expands its utility beyond research labs to clinical workflows that demand rapid, multiplexed analysis of patient‑derived specimens.

From a market perspective, precise single‑EV profiling positions this technology at the intersection of liquid‑biopsy diagnostics, personalized oncology, and nanomedicine. Companies developing EV‑based tests can leverage the high‑throughput, low‑cost nature of the nanowell format to scale assays while maintaining analytical rigor. As regulatory pathways for EV biomarkers mature, platforms that combine spatial control with robust fluorescence quantification are likely to become foundational tools in next‑generation diagnostic kits, driving both scientific insight and commercial opportunity.